555 related articles for article (PubMed ID: 31828967)
1. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
[TBL] [Abstract][Full Text] [Related]
2. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
[TBL] [Abstract][Full Text] [Related]
3. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
6. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
8. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.
Lichtenstein MRL; Nipp RD; Muzikansky A; Goodwin K; Anderson D; Newcomb RA; Gainor JF
J Thorac Oncol; 2019 Mar; 14(3):547-552. PubMed ID: 30476576
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
[TBL] [Abstract][Full Text] [Related]
11. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
12. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
[TBL] [Abstract][Full Text] [Related]
15. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
20. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.
Youn B; Trikalinos NA; Mor V; Wilson IB; Dahabreh IJ
Cancer; 2020 Mar; 126(5):978-985. PubMed ID: 31943163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
